CIRCULATE-Japan project led by Dr. Yoshino, chairman of 22CEMIT and Chief of Gastrointestinal Medicine at National Cancer Center East Hospital, was introduced in Shukan Shincho.

CIRCULATE-Japan, a large-scale physician-initiated clinical trial project led by Dr. Takayuki Yoshino, the chairman of our organization, was featured in a 4-page article in Shukan Shincho (Nov. 19 issue, on sale Nov. 12), introducing its efforts and significance.

CIRCULATE-Japan aims to provide appropriate medical care by estimating the risk of postoperative recurrence more precisely for each patient using the latest liquid biopsy analysis technology. Currently, CIRCULATE-Japan is conducting the world's largest physician-led global clinical trials (GALAXY, VEGA, and ALTAIR) with approximately 150 domestic and overseas sites, including one site in Taiwan.

Currently, postoperative adjuvant chemotherapy is standardly administered after colorectal cancer surgery in order to prevent recurrence according to the risk of recurrence estimated from the stage of the disease. However, the efficacy and side effects of the drugs vary from patient to patient, and peripheral neuropathy (numbness in the hands and feet) is a particular problem that remains as an after-effect. It is hoped that CIRCULATE-Japan can solve this problem.

National Cancer Center's release on CIRCULATE-Japan

Shukan Shincho website

Back to top